Coeptis Therapeutics, Inc. (COEP)
COEP Stock Price Chart
Explore Coeptis Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze COEP price movements and trends.
COEP Company Profile
Discover essential business fundamentals and corporate details for Coeptis Therapeutics, Inc. (COEP) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
17 Dec 2020
Employees
5.00
Website
https://coeptispharma.comCEO
David Mehalick
Description
Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.
COEP Financial Timeline
Browse a chronological timeline of Coeptis Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 14 Aug 2025
EPS came in at -$1.17 , while revenue for the quarter reached $200.68K .
Earnings released on 14 May 2025
EPS came in at -$1.11 , while revenue for the quarter reached $62.87K .
Earnings released on 28 Mar 2025
EPS came in at -$1.01 falling short of the estimated -$0.80 by -26.51%, while revenue for the quarter reached $1.86M .
Stock split effective on 31 Dec 2024
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 Nov 2024
EPS came in at -$0.05 matching the estimated -$0.05.
Earnings released on 16 Aug 2024
EPS came in at -$0.08 surpassing the estimated -$0.09 by +11.11%.
Earnings released on 10 May 2024
EPS came in at -$0.08 .
Earnings released on 26 Mar 2024
EPS came in at -$0.11 , while revenue for the quarter reached $1.50M .
Earnings released on 9 Nov 2023
EPS came in at -$0.23 .
Earnings released on 11 Aug 2023
EPS came in at -$0.08 surpassing the estimated -$0.12 by +33.33%.
Earnings released on 15 May 2023
EPS came in at -$0.46 .
Earnings released on 29 Mar 2023
EPS came in at -$0.20 .
Earnings released on 18 Nov 2022
EPS came in at -$0.28 .
Earnings released on 2 Aug 2022
EPS came in at -$0.48 .
Earnings released on 12 May 2022
EPS came in at -$166.75K .
Earnings released on 11 Mar 2022
EPS came in at -$0.30 .
Earnings released on 15 Nov 2021
EPS came in at -$0.29 , while revenue for the quarter reached $9.89K .
Earnings released on 16 Aug 2021
EPS came in at -$0.13 .
Earnings released on 18 May 2021
EPS came in at -$0.10 , while revenue for the quarter reached $75.00K .
Earnings released on 11 Jan 2021
EPS came in at -$302.02 .
Earnings released on 23 Nov 2020
EPS came in at -$8.65 .
COEP Stock Performance
Access detailed COEP performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.